Magic mushrooms are finding their place in the world of mental health and wellness. You don’t want to miss this opportunity to invest.

About Indestructible Wealth: I’m Jack Gibson. I’m your wealth strategist and I’m here to help you make some money. The Indestructible Wealth Podcast is for young entrepreneurs who want to make, keep and grow wealth to enjoy now, and for years to come.

Episode #39 –

Transcription: Psychedelics: Riding the Magic Mushroom Towards Wealth

There’s a global health disaster playing out right now in front of our eyes, and it’s leaving millions in the lurch. According to the World Health Organization (WHO), more than 800 million people worldwide suffer from mental health disorders. And in 2019, the American Foundation to Prevent Suicide estimated there were 1.38 million suicide attempts in the United States alone. Suicide is often the result of a mental health condition like depression, anxiety, stress, or trauma. To help treat these issues, physicians prescribe antidepressants. But their side effects can be brutal, including weakness… digestive problems… fatigue… drowsiness… weight gain… anxiety… even suicidal thoughts.

Even with those patients willing to go through such terrible side effects, one paper found 40– 60% of people who took antidepressants didn’t see improvement… Plus, not only do antidepressants not work for up to 60% of the people who take them… But for those whom they do work… one-third say they stop working completely over time. It’s a total disaster. That’s why medical science is looking for a solution. They need an alternative to traditional antidepressants. And I believe what they’re working on will become a game-changer.

It involves a class of substances people have been using for thousands of years to treat all types of illnesses. But because of fear and hysteria, the government banned them 50 years ago. However, new studies have shown so much promise, the VA has approved it to treat posttraumatic stress disorder (PTSD). A study published in the elite scientific journal Nature showed that when paired with therapy, it was a safe and effective treatment. And the U.S. Food and Drug Administration recently gave it “breakthrough therapy” designation for treatment-resistant depression (TRD). Pharma giant Johnson & Johnson recently released its own FDA approved drug, Spravato, using one of these substances. This breakthrough offers hope to the 2.7 million registered Vietnam War veterans… 660,000 Gulf War vets… and 300,000 Enduring Freedom vets afflicted with PTSD. 

I’m talking about therapeutic compounds that have been isolated from psychedelic drugs… For 50 years, the federal government has banned the use of these plant-based and psychedelic medicines. But recent scientific research shows they have the potential to cure a wide range of mental disorders… including substance abuse, anxiety, and addiction. Together, the addressable market for these treatments is worth trillions. 

Combined, it’s about $2.9 trillion in medical costs and lost productivity due to mental health disorders. However, despite numerous studies demonstrating their efficacy, psychedelics are still illegal at the federal level. But the massive bureaucracy is slowly starting to shift its views on these life-changing compounds. Here’s why… For years, Americans have viewed psychedelic drugs like magic mushrooms, ecstasy, and LSD as “party drugs” with little medical value. So for most people, psychedelics were taboo. 

But recent studies have found measured doses of psychedelic drugs can ease intractable depression… end addictions… and increase a sense of overall wellbeing and joy. No one can argue these are positive results.

Best of all, these shifts seem to be lasting generally after 1-3 doses in a supportive setting. So there’s no need for drawn-out dosing schedules or refills at the pharmacy. That also lowers the chance of developing a reliance, tolerance, or addiction. That’s why I believe psychedelic medicine could be the biggest medical breakout since biotech. We’re not talking about recreational, unregulated use of these compounds. We’re talking about concrete, scientific applications to improve health… boost quality of life… and save lives. This is real medicine prescribed by a doctor, picked up at a pharmacy, or administered in a doctor’s office. And it has the potential to completely upend the traditional pharmaceutical model. 

Now, to be straightforward. Psychedelics face an uphill battle in Congress. Many lawmakers still hold outdated prejudices against these lifesaving treatments. But let me be clear… This is not a legalization story. And this is most certainly not a recreational story. This driving theme behind what Teeka Tiwari at the Palm Beach Group calls his third Trillion-Dollar Trend is a reclassification of psychedelics from Schedule 1 drugs to a lower schedule that decriminalizes and recognizes the huge medical breakthroughs psychedelic compounds represent. Two of the biggest federal agencies have already authorized psychedelic therapies. So the tide is shifting. And while Congress’ current inaction on psychedelics is discouraging for people suffering from mental disorders and their families, here’s the good news… We can use this opportunity to position ourselves at the very early stages of what I believe will be Teeka’s third trillion-dollar trade.

In 1971, President Nixon signed the Controlled Substances Act, which banned the use of psychedelics. At the time, the pharmaceutical industry was about to launch a new slate of traditional-based antidepressant drugs. Big Pharma knew these drugs would be a money-making machine because patients had to take them every day for the rest of their lives. The pharmaceutical industry pressured the government to make plant-based and other psychedelic compounds illegal.  The government propaganda campaign against psychedelics became ingrained in the minds of American society. And it led to many of the misunderstandings and taboo nature of these compounds that still persist today. 

Thanks to the greed and influence of Big Pharma, many people who suffered from mental illnesses couldn’t legally access the treatment options they deserved for decades. This injustice also set back years of research, as testing of these compounds was also restricted. Scientists had to wade through a sea of red tape to study psychedelic compounds. And they risked jail time if they ran afoul of state or federal laws. Things have finally started to shift with the advent of the internet and ease of access to information. People are getting empowered to do their own research. And society is realizing it’s not necessarily in the interest of pharmaceutical companies to cure disease… but rather, just to treat the symptoms. And a group of small innovators emerged that started producing plant-based medicines to treat these diseases at their root.

 Ironically today, the very same pharmaceutical companies that once suppressed them are now coveting them and targeting them for acquisition… Which only makes our opportunity today even sweeter. History will look back on this 50-plus-year prohibition on psychedelic compounds as one of the greatest injustices to human’s mental health. Only recently, in the crisis and aftereffects of COVID-19, has there been a change in how society thinks about these powerful therapeutic compounds. And because of interest ramping up, we believe we’re on the cusp of the next revolution to impact a multi-trilliondollar market. Now, it’s true psychedelics can be dangerous if abused. But the same applies to all drugs. For example, Advil is one of the most dangerous drugs in America – if you take too much of it. And we don’t even need to mention legal substances like cigarettes and alcohol, which kill millions of people each year due to users abusing them. But when it comes to the medical use of drugs, we shouldn’t necessarily frame the argument around what’s legal or illegal… but how the government classifies a drug. Let us explain… 

Today, the government classifies psychedelics as Schedule 1, which includes other drugs like marijuana and heroin. According to the government, these drugs have a high potential for abuse and no currently accepted medical treatment use in the U.S. We believe the category psychedelics belong in and will eventually be reclassified to is Schedule III. Drugs in this category have medical use but may lead to moderate or low physical dependence or high psychological dependence. Schedule III classification would put psychedelic substances in the same category as drugs like Tylenol with codeine, anabolic steroids, and Vicodin. They’d still be regulated… but would also be recognized for their medical benefits. Without going into detail of why Congress will eventually reschedule psychedelics as Schedule III, it’s likely to happen, as several recent events show, including Johnson & Johnson releasing it’s own FDA approved drug, Spravato, to treat people suffering from depression, which uses a chemical cousin of the so called party drug “Special K.”   (I’ve never heard of it, but I’m not in the party scene).  

If you’re still skeptical about psychedelics, I completely understand… For most of us, it’s unfamiliar territory. But we’ve been through revolutions in alternative medicine before. Take beta blockers for instance… This class of drugs is widely used to treat heart conditions. They control heart rhythm  and reduce high blood pressure. The research that resulted in beta blockers dates from the turn of the 20th century. But according to the New York Times, the drugs had to surpass several stumbling blocks in the 1940s before they became widely accepted in the scientific community…The FDA didn’t approve the first beta blockers until 1986. Today, the beta-blocker market is worth more than $19 billion. And companies like Eli Lilly, which developed the first beta blocker  have seen billions in profit. Shares of Eli Lilly jumped 200% in the years following its FDA approval… And today, they’ve returned 3,260% to the most loyal shareholders. 

And that’s our opportunity. The profit potential in psychedelics will be just as lucrative as beta blockers. Even better, I think this market will generate returns much faster. Right now, individual investors have the early advantage over institutions. That’s because institutions have to wait until stocks are large enough to trade on the world’s biggest exchanges. This gives you the opportunity to get in before the institutions… And puts you in a position to be way ahead as these companies develop and a storm of big money finds its way into this space. 

There are five small-cap companies viewed as the best plays to ride this trillion-dollar trend. How do you get your hands on it?   Simple:   Go to my website,, subscribe to my 7 step video series which puts you on the Insider’s Club list, and then respond to one of the emails and request the stock picks.   Please, only do this if you’re very serious and plan on buying these stocks.   Well, definitely get on the email list as you’ll have access to deals that no one else will, but only request the psychedelic stock picks if you plan on taking immediate action.   


Share This